PKC-epsilon inhibitors

作者: Michael A. Pleiss , Jon D. Levine , Robert Owen Messing

DOI:

关键词:

摘要: The present invention relates to new AGC kinase inhibitors, in particular compounds of Formula I or II a stereoisomer, tautomer, racemic, metabolite, pro- pre-drug, salt, hydrate, solvate thereof, wherein Ar, Cy, R 1 , 3 p and n have the meaning defined claims. In particular, more specifically kinases compositions, pharmaceuticals, comprising such uses inhibitors treatment prophylaxis disease.

参考文章(48)
Abdelkarim Sabri, Susan Steinberg, Methods for inhibiting cardiac disorders ,(2002)
Istvan Kaldor, Roger D. Tung, Michael R. Hale, Christopher T. Baker, Eric Steven Furfine, Andrew Spaltenstein, Wieslaw Mieczyslaw Kazmierski, Prodrugs os aspartyl protease inhibitors ,(1998)
William F. Heath, Christopher J. Rito, John H. McDonald, Michael R. Jirousek, Process for preparing BIS-indolyl macrocycles ,(1997)
Zhigang He, Rajeev Sivasankaran, Vuk Koprivica, Axon regeneration with PKC inhibitiors ,(2003)
William K. Hagmann, Malcolm Maccoss, Charles G. Caldwell, Shrenik K. Shah, Karla L. Furman, Kothandaraman Shankaran, Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases Official Gazette of the United States Patent and Trademark Office Patents. ,(1996)
Loubaba Belbaraka, Jaafar Belgoudi, Saba Siddiqi, Jennifer Phipps, Jennifer Arnold, Herve Jouishomme, Suzanne Lacelle, Methods for modulating gap junctions ,(2002)
C Schmitz-Peiffer, Y Sheng, T.J. Biden, L.A. Selbie, Molecular cloning and characterization of PKC iota, an atypical isoform of protein kinase C derived from insulin-secreting cells. Journal of Biological Chemistry. ,vol. 268, pp. 24296- 24302 ,(1993) , 10.1016/S0021-9258(20)80525-0
Peter G. M. Wuts, Theodora W. Greene, Protective groups in organic synthesis ,(1981)